Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18525
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.11
Market Cap
$184.86M
Change (1 day)
-2.55%
Change (1 year)
815.63%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Number of shares outstanding for Cartesian Therapeutics, Inc. (RNAC)
Number of shares outstanding as of October 2026: 0
According to Cartesian Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of October 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Cartesian Therapeutics, Inc. (RNAC) from 2026 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
